Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma-Reference-Cited by-同舟云学术

Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma

Published:2006-06 Issue:6 Volume:7 Page:521-523
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Azizi Amedeo A,Haberler Christine,Czech Thomas,Gupper Astrid,Prayer Daniela,Breitschopf Helene,Acker Till,Slavc Irene

Publisher

Elsevier BV

Subject

Oncology

Reference15 articles.

1. Chemotherapy in alveolar soft part sarcomas. What do we know?;Reichardt;Eur J Cancer,2003

2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

3. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases;Marler;Pediatrics,2002

4. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice;Beecken;J Natl Cancer Inst,2001

5. Antiangiogenic therapy for cancer: current and emerging concepts;Jain;Oncology (Williston Park),2005

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile;NAGOYA J MED SCI;2023

2. Advances in treatment of alveolar soft part sarcoma: an updated review;Japanese Journal of Clinical Oncology;2023-08-25

3. Pathology of Alveolar Soft Part Sarcoma;Advances in Soft Tissue Tumors;2022-09-28

4. The current management of alveolar soft part sarcomas;Medicine;2021-08-06

5. Use of Antiangiogenic Therapies in Pediatric Solid Tumors;Cancers;2021-01-12